Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gentronix has entered into an agreement to provide GlaxoSmithKline with its genotoxicity detection assay GreenScreen HC. Financial terms of the agreement were not released.
Subscribe to our email newsletter
According to Gentronix, GreenScreen HC is the first human cell based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results.
The assay is amenable to high throughput screening, provides additional data for safety profiling, consumes very low quantities of compound and gives rapid results, the company said.
The proprietary reporter based assay reportedly detects all known classes of genotoxic agent and utilizes green fluorescent protein in order to detect GADD-45a up-regulation which is a key indicator of DNA damage.
John Nicholson, CEO and chairman of Gentronix, said: we have worked with GlaxoSmithKline (GSK) previously on the early validation of our technology and are delighted that they will be incorporating GreenScreen HC into their safety evaluation activities. This agreement provides important validation of our technology and demonstrates the value we bring to our customers.
Gentronix is in the development of new screening assays for Genotoxicity testing. Gentronix main focus is in developing and supplying the GreenScreen HC range of cell-based assays to pharmaceutical and fine chemical companies.